Dr William Coley and tumour regression: a place in history or in the future
- PMID: 14707241
- PMCID: PMC1742910
Dr William Coley and tumour regression: a place in history or in the future
Abstract
Spontaneous tumour regression has followed bacterial, fungal, viral, and protozoal infections. This phenomenon inspired the development of numerous rudimentary cancer immunotherapies, with a history spanning thousands of years. Coley took advantage of this natural phenomenon, developing a killed bacterial vaccine for cancer in the late 1800s. He observed that inducing a fever was crucial for tumour regression. Unfortunately, at the present time little credence is given to the febrile response in fighting infections-no less cancer. Rapidly growing tumours contain large numbers of leucocytes. These cells play a part in both defence and repair; however, reparative functions can also support tumour growth. Intratumoural infections may reactivate defensive functions, causing tumour regression. Can it be a coincidence that this method of immunotherapy has been "rediscovered" repeatedly throughout the centuries? Clearly, Coley's approach to cancer treatment has a place in the past, present, and future. It offers a rare opportunity for the development of a broadly applicable, relatively inexpensive, yet effective treatment for cancer. Even in cases beyond the reach of conventional therapy, there is hope.
Similar articles
-
Spontaneous regression: a hidden treasure buried in time.Med Hypotheses. 2002 Feb;58(2):115-9. doi: 10.1054/mehy.2001.1469. Med Hypotheses. 2002. PMID: 11812185
-
Talkin' Toxins: From Coley's to Modern Cancer Immunotherapy.Toxins (Basel). 2020 Apr 9;12(4):241. doi: 10.3390/toxins12040241. Toxins (Basel). 2020. PMID: 32283684 Free PMC article. Review.
-
Coley's toxins, tumor necrosis factor and cancer research: a historical perspective.Pharmacol Ther. 1994;64(3):529-64. doi: 10.1016/0163-7258(94)90023-x. Pharmacol Ther. 1994. PMID: 7724661 Review.
-
Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited.Cytokine Growth Factor Rev. 2009 Aug;20(4):271-81. doi: 10.1016/j.cytogfr.2009.07.004. Epub 2009 Aug 4. Cytokine Growth Factor Rev. 2009. PMID: 19656718
-
The 2018 Nobel Prize in medicine goes to cancer immunotherapy (editorial for BMC cancer).BMC Cancer. 2018 Nov 12;18(1):1086. doi: 10.1186/s12885-018-5020-3. BMC Cancer. 2018. PMID: 30415640 Free PMC article. No abstract available.
Cited by
-
Cancer's second genome: Microbial cancer diagnostics and redefining clonal evolution as a multispecies process: Humans and their tumors are not aseptic, and the multispecies nature of cancer modulates clinical care and clonal evolution: Humans and their tumors are not aseptic, and the multispecies nature of cancer modulates clinical care and clonal evolution.Bioessays. 2022 May;44(5):e2100252. doi: 10.1002/bies.202100252. Epub 2022 Mar 6. Bioessays. 2022. PMID: 35253252 Free PMC article. Review.
-
Functional immune boosters; the herb or its dead microbiome? Antigenic TLR4 agonist MAMPs found in 65 medicinal roots and algae's.J Funct Foods. 2023 Aug;107:105687. doi: 10.1016/j.jff.2023.105687. Epub 2023 Jul 29. J Funct Foods. 2023. PMID: 37654434 Free PMC article.
-
Spontaneous regression of pancreatic cancer: A case report and literature review.Int J Surg Case Rep. 2018;42:55-59. doi: 10.1016/j.ijscr.2017.11.056. Epub 2017 Dec 2. Int J Surg Case Rep. 2018. PMID: 29216532 Free PMC article.
-
Dynamic Fluorescence Imaging of Orally-administered Tumor-targeting Salmonella typhimurium A1-R Expressing Green Fluorescent Protein Trafficking Through the Gastrointestinal System to Target Fibrosarcomas in Nude Mice.In Vivo. 2025 Mar-Apr;39(2):640-647. doi: 10.21873/invivo.13869. In Vivo. 2025. PMID: 40010967 Free PMC article.
-
The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.Mol Ther. 2013 Feb;21(2):348-57. doi: 10.1038/mt.2012.204. Epub 2012 Sep 25. Mol Ther. 2013. PMID: 23011032 Free PMC article.
References
Publication types
MeSH terms
Substances
Personal name as subject
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous